Transsexualism and osteoporosis.
Schlatterer K, Auer DP, Yassouridis A, von
Werder K, Stalla GK.
Dept. of Endocrinology, Max
Planck Institute of Psychiatry, Munich, Germany.
Abstract [Full Text] [PDF]
Abstract
The aim of this study was to investigate
whether and to what extent our regime of cross-gender hormone replacement
therapy might influence osteoporosis development in transsexual patients.
We found that after long-term therapy the
bone densities of our cross-gender hormone-treated transsexual groups (10
male-to-female and 10 female-to-male) did not show significant differences
compared to those of the corresponding biological sex. Moreover, the
bone-density during therapy pointed out very little variability and that
independent of the gender-alteration (transsexuality-direction) and the age
of the transsexuals.
Our results indicate that for transsexual
patients treated with cross-gender hormone replacement therapy the risk of
developing osteoporosis is low.
Citation:
Clin Endocrinol Diabetes 1998;106(4):365-8 an
article published on the Internet by PubMed <http://www.ncbi.nlm.nih.gov/>
